Abstract:: Basal cell carcinoma (BCC) is by far the most common human skin cancer. In Caucasians, BCCs account for around 90% of periocular malignancies. However, periocular BCCs are usually neglected due to their slow and painless growth, unless presenting complaints, e.g., large size, bleeding, recurrent infections of the tumor, or secondary symptoms resulting from adjacent structures involvement as epiphora, limited eye globe motility as well as globe displacement. Moreover, although the tumor can usually be cured with local excision, local recurrence can occur in up to 20% of eyelid BCC cases. Recurrent BCCs of the eyelid show a poorer overall prognosis than the primary ones. In addition, the management of advanced diseases, such as orbital or intracranial invasion as well as metastatic lesions, is challenging and often involves a multidisciplinary approach. In this paper, we reviewed the recent research progress of pathogenesis, clinical presentation, and therapeutics of periocular BCCs. We introduced the molecular pathogenesis of BCCs [multi-step ultraviolet (UV)-induced carcinogenesis model, genetic predisposition, and epigenetic changes], clinical classification, and tumor-node-metastasis (TNM) clinically stage of eyelid skin BCCs. We also emphasized the treatment of BCCs, i.e., surgical resection, oculoplastic reconstruction, and alternative therapies (radiation therapy, systemic therapy, topical therapy, and prophylactic therapy). In the end, we proposed that considering the possible iatrogenic damage to the surface of the eye by surgical excision, the treatment of periocular BCCs is recommended to be performed by or in the presence of an oculoplastic surgeon. (FFS), and fast paraffin (FP). Phan et al. performed a meta-analysis comparing recurrence rates of MMS, intraoperative FSE controlled excision, and wide local excision (WLE) with predetermined margins as well as paraffin section evaluation (37). The pooled recurrence rates for periocular BCCs following MMS, FSE, and WLE were 2.9% (95% CI, 1.9–4.4%, an average follow-up of 48.8±14.9 months), 1.9% (95% CI, 1.9–2.4%, an average follow-up of 70.7±48.0 months), and 5.9% (95% CI, 3.9–8.9%, an average follow-up of 49.2±29.3 months), respectively. Meta-regression analysis illustrated an insignificantly similar recurrence rate for MMS and FFS (P>0.05) and a significantly lower one in comparison to WLE without FSE.

The role of electrochemotherapy in the treatment of locally advanced or recurrent eyelid‐periocular basal cell carcinoma: long‐term results

The Long-Term Results of Electrochemotherapy in the Treatment of Patients with Locoregionally Advanced, Unresectable Melanoma

Electrochemotherapy for the treatment of cutaneous squamous cell carcinoma: The INSPECT experience (2008-2020)

Long-term results after surgical basal cell carcinoma excision in the eyelid region: revisited

Clinicopathologic Features And Prognostic Factors Of Malignant Eyelid Tumors

Surgical Bedside Electrochemotherapy for Local Control of a Recurrent Phylloid Malignant Breast Tumor: A Case Report

Mohs micrographic surgery for eyelid sebaceous carcinoma: A multicenter cohort of 360 patients.

Treatment strategies with electrochemotherapy for limb in-transit melanoma: Real-world outcomes from a European, retrospective, cohort study

Electrochemotherapy in Kaposi's Sarcoma Patients: From the Gold Standard Strategy to Locally Advanced Cutaneous and Subcutaneous Lesions

Electrochemotherapy for treatment of skin and soft tissue tumours. Update and definition of its role in multimodal therapy

Recurrent squamous cell carcinoma of the upper eyelid treated with combination therapy of ALA photodynamic therapy and surgery with secondary healing

Description of outcome and adverse events in 21 cats with locally advanced nasal planum squamous cell carcinoma treated with electrochemotherapy

Periocular Basal Cell Carcinoma—current Treatment Concepts

Electrochemotherapy as a Trigger to Overcome Primary Resistance to Anti-PD-1 Treatment: A Case Report of Melanoma of the Scalp

Erdheim–Chester Disease With Eyelid and Orbital Involvement: A Review of Treatment Modalities at One Institution From 2014 to 2022

Recurrence in Eyelid Sebaceous Carcinoma: A Multicentric Study of 418 Patients.

Electrochemical Therapy in the Treatment of Malignant Tumours on the Body Surface.

Results of Mohs’ Micrographic Surgery of Periocular Basal Cell Carcinoma: The Swedish Experience

Electrochemical therapy (EChT) of cancer tumor with an external anode, a way to achieve pathological complete response

Alternative treatment options for periocular basal cell carcinoma: a narrative review

Neoadjuvant Chemotherapy in Non-Metastatic Eyelid Sebaceous Gland Carcinoma: A Report in 10 Cases